VolitionRx Posts $7.3 Million Loss as Revenue Stalls but Sepsis Prototype and Sysmex Deal Signal Pipeline Progress

VolitionRx reported flat Q2 revenue of approximately $400,000 and a widening net loss of $7.3 million despite a 32% operating cost reduction, as management pivoted investor attention to a finger-prick lateral flow prototype for sepsis detection and a new collaboration with Sysmex that extends the company’s diagnostic partnership network alongside existing work with Werfen.

VolitionRX said second-quarter revenue was broadly unchanged at about $400,000, as weaker Nu.Q Discover services income offset the usual timing effects in its project pipeline. The company’s net loss widened to $7.3 million from $6.3 million a year earlier, helped only partly by a 32% reduction in operating costs and a 27% cut in headcount, according to the GuruFocus report on the earnings call.

Management stressed the scientific pipeline rather than the near-term numbers. Chief executive Cameron Reynolds said the company’s Nu.Q Nets sepsis work has reached a point where a finger-prick lateral flow prototype can detect nucleosomes, potentially opening point-of-care and home-testing markets. Volition also disclosed a new collaboration with Sysmex, adding to its existing work with Werfen.

The company highlighted other milestones, including a peer-reviewed paper on its Capture-Seek liquid-biopsy platform and strong feline lymphoma data for its veterinary assay. Volition said publication of that study should trigger a $5 million milestone payment, although peer review is taking longer than expected.

Cash remains tight. Volition ended the quarter with about $2.8 million and burned $5.2 million from operations. Management said it will not give 2026 revenue guidance, underscoring the unpredictability of commercial progress.